Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylsuccinic acid (often referred to as phenylsuccinate) is a dicarboxylic acid derivative that acts as a competitive inhibitor of mitochondrial transport carriers, specifically the dicarboxylate carrier (DIC; SLC25A10) and the oxoglutarate carrier (OGC; SLC25A11). By blocking these carriers, phenylsuccinic acid inhibits the malate-aspartate shuttle, which is essential for transferring reducing equivalents (NADH) from the cytosol into the mitochondrial matrix. In pancreatic islet research, it has been utilized to study metabolic coupling, demonstrating that inhibition of the malate-aspartate shuttle selectively abolishes glucose-provoked glucagon secretion from alpha-cells without affecting insulin secretion from beta-cells. It is primarily employed as a research-use-only laboratory tool to investigate mitochondrial transport, cellular respiration, and metabolic pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylsuccinic acid.